Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,772 total articles
Westport Fuel Systems Inc. announced that the British Columbia Securities Commission has issued a temporary management cease trade order (MCTO) restricting trading by the CEO and CFO due to a cybersecurity incident which delayed the company's filing of its annual financial statements and related disclosures. The company is actively investigating th…
Descartes Systems Group announced that ER2, an Arizona-based IT asset management company, is utilizing Descartes' Sellercloud platform to unify inventory, warehouse, and shipping operations across eight warehouses. This integration led to a 75% improvement in picking speed, reduced shipping errors, and lower shipping costs, supporting ER2's growth …
JD.com, a leading supply chain-based technology and service provider, announced the pricing of CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes via offshore transactions under Regulation S. The offering consists of CNY7.5 billion of 2.05% notes due 2031 and CNY2.5 billion of 2.75% notes due 2036. Proceeds will be u…
Ocugen, Inc. announced the early completion of dosing in its Phase 2/3 GARDian3 clinical trial for OCU410ST, a potential first-in-class modifier gene therapy for Stargardt disease. The trial enrolled 63 patients and aims to evaluate efficacy and safety in slowing the progression of this inherited retinal disorder. Interim data is expected in Q3 202…
Pasithea Therapeutics announced that the FDA has granted Fast Track designation to PAS-004, its next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). This designation facilitates more frequent communication with the FDA, rolling review processes, and may enable accele…
Tiziana Life Sciences announced positive preclinical results demonstrating that their lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, can reduce neuroinflammation and improve cognition in aging-related models. These results support its potential use in treating neurodegenerative conditions and cognitive decline ass…
Apollomics Inc., a clinical-stage biopharmaceutical company focused on oncology therapies, announced $2 million unsecured convertible promissory note financing from its CEO. The funds will support clinical development and corporate operations, with conversion linked to a future equity financing event. The financing terms were approved by the indepe…
NewGenIVF Group Limited announced the filing of its 2025 annual report on Form 20-F with the SEC. The company operates a diversified business spanning real estate development in the UAE, digital asset and DeFi solutions, and reproductive health services in Asia. The report highlights strategic initiatives across these sectors and discloses associat…
B2Gold Corp. has announced the renewal of its normal course issuer bid (NCIB), allowing the company to repurchase up to 132.7 million shares, equivalent to 10% of its public float, over the next 12 months. This move aligns with B2Gold's strategy to return value to shareholders and reflects management's belief that the shares may be undervalued. Sha…
Axsome Therapeutics has acquired exclusive global rights to balipodect (TAK-063), a selective PDE10A inhibitor from Takeda. The company plans to develop balipodect for schizophrenia and Tourette syndrome, initiating Phase 3 trial-enabling activities for schizophrenia in 2026. Balipodect represents a potential first-in-class mechanism targeting neur…
Eldorado Gold Corporation and Foran Mining Corporation announced upcoming shareholder meetings for approval of a proposed plan of arrangement wherein Eldorado will acquire Foran, making it a wholly-owned subsidiary. The combined entity aims to leverage Eldorado's financial strength and operational platform with Foran's copper growth projects, targe…
Lightbridge Corporation announced receiving a Notice of Allowance from the USPTO for a new U.S. patent covering its advanced spirally twisted, multi-lobed metallic fuel assemblies designed for pressurized heavy-water reactors including CANDU-type designs. This strengthens their intellectual property portfolio for their advanced nuclear fuel technol…
BioXcel Therapeutics announced that the FDA has accepted its supplemental New Drug Application for IGALMI® to be used in the at-home setting to acutely treat agitation associated with bipolar disorders or schizophrenia. The FDA set a PDUFA action date of November 14, 2026. This approval could introduce the first FDA-approved at-home treatment for a…
Ocular Therapeutix, Inc. announced plans to present new data from their Phase 3 clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration at upcoming scientific conferences in April 2026. The presentations aim to highlight the drug's efficacy and support its therapeutic potential, with sessions scheduled at the Vit-Buckle Society…
FitLife Brands announced its Q4 and full-year 2025 financial results highlighting a 73% increase in Q4 revenue and a 26% increase for the full year, largely fueled by the recent acquisition of Irwin Naturals. Despite growth in total and wholesale revenues, gross margins declined due to Irwin's historically lower margins and amortization expenses. N…
Brookfield Renewable, a leading global renewable power and sustainable solutions company, will release its first quarter 2026 results on May 1, 2026, followed by a conference call and webcast to discuss financial results and business initiatives. The company operates a diverse renewable energy portfolio including hydroelectric, wind, solar, and sto…
Macerich, a prominent REIT specializing in retail real estate across key U.S. markets, has scheduled the release of its Q1 2026 earnings report for May 6, 2026, following market close. Management will host a conference call the same day to discuss the results. The company continues to focus on its portfolio and environmental, social, and governance…
Telix Pharmaceuticals Limited announced the appointment of David Gill as a Non-Executive Director effective May 11, 2026, with expectations that he will become Chair, succeeding Dr. Mark Nelson. Gill brings over 35 years of biotech and medical device leadership experience, including expertise in U.S. capital markets, positioning Telix for stronger …
Tilray Brands, Inc. reported record third quarter fiscal 2026 results driven by 11% net revenue growth to $207 million and a 6% increase in gross profit to $55 million. The company exhibited strong international cannabis revenue growth of 73% year-over-year, solidifying its leadership in the Canadian cannabis market. The recent acquisition of BrewD…
RYTHM, Inc. announced amendments to its trademark and recipe license agreements with Green Thumb Industries, resulting in a fixed annual cash fee of $70 million with escalations tied to the Consumer Price Index. This new structure provides predictability and stability in revenue, supporting RYTHM's Nasdaq listing and strategic market position in th…
Rapport Therapeutics announced it will present new 8-week follow-up data from its Phase 2a trial of RAP-219, a novel targeted treatment for focal onset seizures, at the 2026 American Academy of Neurology Annual Meeting. RAP-219 specifically modulates the TARP-γ8 AMPA receptor subunit, potentially offering improved efficacy and tolerability for neur…
Brookfield Infrastructure Partners will release its first quarter 2026 results on April 29, 2026, with a conference call and webcast scheduled on the same day. The company operates global infrastructure assets across utilities, transport, midstream, and data sectors, focusing on assets with contracted and regulated revenues to ensure stable cash fl…
RenX Enterprises Corp. reported fiscal year 2025 financial results, highlighting $8.2 million in post-acquisition revenue—17% above guidance—after acquiring Resource Group US Holdings LLC. The company completed the buildout of its Myakka City biomass processing facility, initiated deliveries into the premium compost market, retired $11.9 million in…
Dyne Therapeutics announced participation at the 2026 AMCP Conference with presentations on clinical trial data supporting their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) therapeutics. The company is preparing for potential U.S. launches of DMD treatment next year and DM1 treatment in early 2028, focusing on payer engage…
Medicus Pharma Ltd. provided clarification on its Phase 2 clinical trial data for SkinJect, a doxorubicin-containing microneedle array for nodular basal cell carcinoma treatment. The company emphasized the therapeutic importance of the active drug arms over the device-only arm, highlighting that the 200µg dose cohort demonstrated the most promising…
